Clinical trial

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

NCT02923180

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2017-02-14

PhasePHASE2

Study timeline

Study start (actual)2017-02-14Date precision: day

Registry last updated2026-08-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

EnoblituzumabDRUG

Sponsors & collaborators

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkinslead sponsor

MacroGenicscollaborator

Mapped research locations

BaltimoreMaryland, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02923180 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.